際際滷shows by User: nmslabs / http://www.slideshare.net/images/logo.gif 際際滷shows by User: nmslabs / Thu, 25 Apr 2013 14:13:29 GMT 際際滷Share feed for 際際滷shows by User: nmslabs Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone Cases /slideshow/increasing-diversity-of-chemicals-in-synthetic-stimulant-and-cathinone-cases/19977103 november2012nmslabscathinoneswebinar-130425141329-phpapp02
Hosted by NMS Labs, Tuesday, November 27, 2012 Presented by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services Dr. Barry Logan, Director of Forensic and Toxicological Services at NMS Labs, presents some of the latest developments in the designer drug arena from the perspective of NMS Labs. What started with Bath Salts has evolved into a complex culture of experimentation with Research Chemicals. With the changes in the law that took place in the summer of 2012, and some high profile enforcement action, the flagrant public sale of the products has moved under the counter and into the back room. Suppliers are diversifying the range of chemicals that appear in these products however, and an alarming number of deaths and adverse events have been reported. Currently, MDPV, methylone, alpha-PVP, pentedrone, 25-I NBOMe, and the stimulant nutritional compound DMAA are among the most frequently encountered drugs in our toxicology populations. This webinar reviews a comprehensive LC-TOF application for screening for designer stimulants and cathinones, and emerging data on their prevalence and adverse effects.]]>
Hosted by NMS Labs, Tuesday, November 27, 2012 Presented by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services Dr. Barry Logan, Director of Forensic and Toxicological Services at NMS Labs, presents some of the latest developments in the designer drug arena from the perspective of NMS Labs. What started with Bath Salts has evolved into a complex culture of experimentation with Research Chemicals. With the changes in the law that took place in the summer of 2012, and some high profile enforcement action, the flagrant public sale of the products has moved under the counter and into the back room. Suppliers are diversifying the range of chemicals that appear in these products however, and an alarming number of deaths and adverse events have been reported. Currently, MDPV, methylone, alpha-PVP, pentedrone, 25-I NBOMe, and the stimulant nutritional compound DMAA are among the most frequently encountered drugs in our toxicology populations. This webinar reviews a comprehensive LC-TOF application for screening for designer stimulants and cathinones, and emerging data on their prevalence and adverse effects.]]> Thu, 25 Apr 2013 14:13:29 GMT /slideshow/increasing-diversity-of-chemicals-in-synthetic-stimulant-and-cathinone-cases/19977103 nmslabs@slideshare.net(nmslabs) Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone Cases nmslabs Hosted by NMS Labs, Tuesday, November 27, 2012 Presented by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services Dr. Barry Logan, Director of Forensic and Toxicological Services at NMS Labs, presents some of the latest developments in the designer drug arena from the perspective of NMS Labs. What started with Bath Salts has evolved into a complex culture of experimentation with Research Chemicals. With the changes in the law that took place in the summer of 2012, and some high profile enforcement action, the flagrant public sale of the products has moved under the counter and into the back room. Suppliers are diversifying the range of chemicals that appear in these products however, and an alarming number of deaths and adverse events have been reported. Currently, MDPV, methylone, alpha-PVP, pentedrone, 25-I NBOMe, and the stimulant nutritional compound DMAA are among the most frequently encountered drugs in our toxicology populations. This webinar reviews a comprehensive LC-TOF application for screening for designer stimulants and cathinones, and emerging data on their prevalence and adverse effects. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/november2012nmslabscathinoneswebinar-130425141329-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Hosted by NMS Labs, Tuesday, November 27, 2012 Presented by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services Dr. Barry Logan, Director of Forensic and Toxicological Services at NMS Labs, presents some of the latest developments in the designer drug arena from the perspective of NMS Labs. What started with Bath Salts has evolved into a complex culture of experimentation with Research Chemicals. With the changes in the law that took place in the summer of 2012, and some high profile enforcement action, the flagrant public sale of the products has moved under the counter and into the back room. Suppliers are diversifying the range of chemicals that appear in these products however, and an alarming number of deaths and adverse events have been reported. Currently, MDPV, methylone, alpha-PVP, pentedrone, 25-I NBOMe, and the stimulant nutritional compound DMAA are among the most frequently encountered drugs in our toxicology populations. This webinar reviews a comprehensive LC-TOF application for screening for designer stimulants and cathinones, and emerging data on their prevalence and adverse effects.
Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone Cases from NMS Labs
]]> 2211 8 https://cdn.slidesharecdn.com/ss_thumbnails/november2012nmslabscathinoneswebinar-130425141329-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 The Challenges of Analytical Method Validation for Hallucinogens and Designer Stimulants in Biological Samples Using LC-TOF /slideshow/the-challenges-of-analytical-method-validation-for-hallucinogens-and-designer-stimulants-in-biological-samples-using-lctof/14673342 agilentoctobertofseminarupdated-121010142551-phpapp02
The Challenges of Analytical Method Validation for Hallucinogens and Designer Stimulants in Biological Samples Using LC-TOF Hosted by Agilent Technologies on October 8, 2012 Presented by Barry K Logan, Ph.D., NMS Labs National Director, Forensic Services]]>
The Challenges of Analytical Method Validation for Hallucinogens and Designer Stimulants in Biological Samples Using LC-TOF Hosted by Agilent Technologies on October 8, 2012 Presented by Barry K Logan, Ph.D., NMS Labs National Director, Forensic Services]]> Wed, 10 Oct 2012 14:25:50 GMT /slideshow/the-challenges-of-analytical-method-validation-for-hallucinogens-and-designer-stimulants-in-biological-samples-using-lctof/14673342 nmslabs@slideshare.net(nmslabs) The Challenges of Analytical Method Validation for Hallucinogens and Designer Stimulants in Biological Samples Using LC-TOF nmslabs The Challenges of Analytical Method Validation for Hallucinogens and Designer Stimulants in Biological Samples Using LC-TOF Hosted by Agilent Technologies on October 8, 2012 Presented by Barry K Logan, Ph.D., NMS Labs National Director, Forensic Services <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/agilentoctobertofseminarupdated-121010142551-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> The Challenges of Analytical Method Validation for Hallucinogens and Designer Stimulants in Biological Samples Using LC-TOF Hosted by Agilent Technologies on October 8, 2012 Presented by Barry K Logan, Ph.D., NMS Labs National Director, Forensic Services
The Challenges of Analytical Method Validation for Hallucinogens and Designer Stimulants in Biological Samples Using LC-TOF from NMS Labs
]]> 1226 2 https://cdn.slidesharecdn.com/ss_thumbnails/agilentoctobertofseminarupdated-121010142551-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Trends Report on Changes in the Designer Drug Market: Spring 2012 /slideshow/trends-report-on-changes-in-the-designer-drug-market-spring-2012/13078610 designerdrugspringupdatebklwebinarmay2012-120525134751-phpapp02
Dr. Barry K. Logan, NMS Labs National Director of Forensic and Toxicological Services, presents fascinating new data on how the identity of compounds available in the synthetic drug market place (cannabinoids and bath salts) has changed quarter by quarter since 2010. Compounds have come and gone largely to avoid attempts to schedule them, but some have emerged as major chemicals of concern. New compounds are now starting to appear, making obsolete even the latest changes in State and Federal laws designed to control this dangerous and rapidly growing market. Although the synthetic cannabinoid drugs have changed the most, the Bath Salts/Plant Food craze has recently developed momentum and is showing signs of expanding in scale and scope. After reviewing the trends in drug availability and their impact on forensic chemistry labs, the presentation considers the challenges faced by toxicology labs in monitoring synthetic drug use as the menu of substances popular among drug abusers has grown and diversified, and how technological advances are helping with that effort. The presentation concludes with the latest research reports on adverse effects of the use of these drugs and consideration of what we might expect through the rest of 2012.]]>
Dr. Barry K. Logan, NMS Labs National Director of Forensic and Toxicological Services, presents fascinating new data on how the identity of compounds available in the synthetic drug market place (cannabinoids and bath salts) has changed quarter by quarter since 2010. Compounds have come and gone largely to avoid attempts to schedule them, but some have emerged as major chemicals of concern. New compounds are now starting to appear, making obsolete even the latest changes in State and Federal laws designed to control this dangerous and rapidly growing market. Although the synthetic cannabinoid drugs have changed the most, the Bath Salts/Plant Food craze has recently developed momentum and is showing signs of expanding in scale and scope. After reviewing the trends in drug availability and their impact on forensic chemistry labs, the presentation considers the challenges faced by toxicology labs in monitoring synthetic drug use as the menu of substances popular among drug abusers has grown and diversified, and how technological advances are helping with that effort. The presentation concludes with the latest research reports on adverse effects of the use of these drugs and consideration of what we might expect through the rest of 2012.]]> Fri, 25 May 2012 13:47:47 GMT /slideshow/trends-report-on-changes-in-the-designer-drug-market-spring-2012/13078610 nmslabs@slideshare.net(nmslabs) Trends Report on Changes in the Designer Drug Market: Spring 2012 nmslabs Dr. Barry K. Logan, NMS Labs National Director of Forensic and Toxicological Services, presents fascinating new data on how the identity of compounds available in the synthetic drug market place (cannabinoids and bath salts) has changed quarter by quarter since 2010. Compounds have come and gone largely to avoid attempts to schedule them, but some have emerged as major chemicals of concern. New compounds are now starting to appear, making obsolete even the latest changes in State and Federal laws designed to control this dangerous and rapidly growing market. Although the synthetic cannabinoid drugs have changed the most, the Bath Salts/Plant Food craze has recently developed momentum and is showing signs of expanding in scale and scope. After reviewing the trends in drug availability and their impact on forensic chemistry labs, the presentation considers the challenges faced by toxicology labs in monitoring synthetic drug use as the menu of substances popular among drug abusers has grown and diversified, and how technological advances are helping with that effort. The presentation concludes with the latest research reports on adverse effects of the use of these drugs and consideration of what we might expect through the rest of 2012. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/designerdrugspringupdatebklwebinarmay2012-120525134751-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Dr. Barry K. Logan, NMS Labs National Director of Forensic and Toxicological Services, presents fascinating new data on how the identity of compounds available in the synthetic drug market place (cannabinoids and bath salts) has changed quarter by quarter since 2010. Compounds have come and gone largely to avoid attempts to schedule them, but some have emerged as major chemicals of concern. New compounds are now starting to appear, making obsolete even the latest changes in State and Federal laws designed to control this dangerous and rapidly growing market. Although the synthetic cannabinoid drugs have changed the most, the Bath Salts/Plant Food craze has recently developed momentum and is showing signs of expanding in scale and scope. After reviewing the trends in drug availability and their impact on forensic chemistry labs, the presentation considers the challenges faced by toxicology labs in monitoring synthetic drug use as the menu of substances popular among drug abusers has grown and diversified, and how technological advances are helping with that effort. The presentation concludes with the latest research reports on adverse effects of the use of these drugs and consideration of what we might expect through the rest of 2012.
Trends Report on Changes in the Designer Drug Market: Spring 2012 from NMS Labs
]]> 1915 7 https://cdn.slidesharecdn.com/ss_thumbnails/designerdrugspringupdatebklwebinarmay2012-120525134751-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 The Expanding Reach of the Designer Drug Movement in 2011: Challenges for Forensic Toxicology & Chemistry /nmslabs/the-expanding-reach-of-the-designer-drug-movement-in-2011-challenges-for-forensic-toxicology-chemistry designerdrugwebinar102611-120525132121-phpapp01
This presentation considers the latest intelligence on what drugs are out in the U.S. grey market of products being sold as novelties, legal highs, Bath Salts and research chemicals, including an update on the latest trends in synthetic cannabinoid use and detection. The proliferation of designer drugs in the last two years has made a remarkable change to the landscape of forensic toxicology and drug identification. The scope of compounds that require detection and measurement has grown from a few drugs that needed to be targeted in specific cases, to a wide range of esoteric compounds that arguably need to be included in general drug screens for forensic purposes. The growth continues as the industry that has built up around recreational drug manufacture adjusts in an attempt to stay one step ahead of the law. The presentation reviews the general chemical drug classes encountered in forensic toxicology and chemistry casework, including mephedrone, methylone and MDPV, recently scheduled by the US DEA, and related the cathinones, 2C compounds, tryptamines, and pyrovalerones. This includes a survey of the latest published research, and a review of resources for analytical testing and standards. ]]>
This presentation considers the latest intelligence on what drugs are out in the U.S. grey market of products being sold as novelties, legal highs, Bath Salts and research chemicals, including an update on the latest trends in synthetic cannabinoid use and detection. The proliferation of designer drugs in the last two years has made a remarkable change to the landscape of forensic toxicology and drug identification. The scope of compounds that require detection and measurement has grown from a few drugs that needed to be targeted in specific cases, to a wide range of esoteric compounds that arguably need to be included in general drug screens for forensic purposes. The growth continues as the industry that has built up around recreational drug manufacture adjusts in an attempt to stay one step ahead of the law. The presentation reviews the general chemical drug classes encountered in forensic toxicology and chemistry casework, including mephedrone, methylone and MDPV, recently scheduled by the US DEA, and related the cathinones, 2C compounds, tryptamines, and pyrovalerones. This includes a survey of the latest published research, and a review of resources for analytical testing and standards. ]]> Fri, 25 May 2012 13:21:17 GMT /nmslabs/the-expanding-reach-of-the-designer-drug-movement-in-2011-challenges-for-forensic-toxicology-chemistry nmslabs@slideshare.net(nmslabs) The Expanding Reach of the Designer Drug Movement in 2011: Challenges for Forensic Toxicology & Chemistry nmslabs This presentation considers the latest intelligence on what drugs are out in the U.S. grey market of products being sold as novelties, legal highs, Bath Salts and research chemicals, including an update on the latest trends in synthetic cannabinoid use and detection. The proliferation of designer drugs in the last two years has made a remarkable change to the landscape of forensic toxicology and drug identification. The scope of compounds that require detection and measurement has grown from a few drugs that needed to be targeted in specific cases, to a wide range of esoteric compounds that arguably need to be included in general drug screens for forensic purposes. The growth continues as the industry that has built up around recreational drug manufacture adjusts in an attempt to stay one step ahead of the law. The presentation reviews the general chemical drug classes encountered in forensic toxicology and chemistry casework, including mephedrone, methylone and MDPV, recently scheduled by the US DEA, and related the cathinones, 2C compounds, tryptamines, and pyrovalerones. This includes a survey of the latest published research, and a review of resources for analytical testing and standards. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/designerdrugwebinar102611-120525132121-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> This presentation considers the latest intelligence on what drugs are out in the U.S. grey market of products being sold as novelties, legal highs, Bath Salts and research chemicals, including an update on the latest trends in synthetic cannabinoid use and detection. The proliferation of designer drugs in the last two years has made a remarkable change to the landscape of forensic toxicology and drug identification. The scope of compounds that require detection and measurement has grown from a few drugs that needed to be targeted in specific cases, to a wide range of esoteric compounds that arguably need to be included in general drug screens for forensic purposes. The growth continues as the industry that has built up around recreational drug manufacture adjusts in an attempt to stay one step ahead of the law. The presentation reviews the general chemical drug classes encountered in forensic toxicology and chemistry casework, including mephedrone, methylone and MDPV, recently scheduled by the US DEA, and related the cathinones, 2C compounds, tryptamines, and pyrovalerones. This includes a survey of the latest published research, and a review of resources for analytical testing and standards.
The Expanding Reach of the Designer Drug Movement in 2011: Challenges for Forensic Toxicology & Chemistry from NMS Labs
]]> 1801 11 https://cdn.slidesharecdn.com/ss_thumbnails/designerdrugwebinar102611-120525132121-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Pharmacodynamics and Pharmacokinetics of Synthetic Cannabinoids /slideshow/pharmacodynamics-and-pharmacokinetics-of-synthetic-cannabinoids/11888334 pharmofsyntheticcann021712-120306102410-phpapp01
Presented on February 21, 2012 at the AAFS 64th Annual Scientific Meeting by Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services and Wendy R. Adams, Ph.D., DABFT, Forensic Toxicologist ]]>
Presented on February 21, 2012 at the AAFS 64th Annual Scientific Meeting by Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services and Wendy R. Adams, Ph.D., DABFT, Forensic Toxicologist ]]> Tue, 06 Mar 2012 10:24:09 GMT /slideshow/pharmacodynamics-and-pharmacokinetics-of-synthetic-cannabinoids/11888334 nmslabs@slideshare.net(nmslabs) Pharmacodynamics and Pharmacokinetics of Synthetic Cannabinoids nmslabs Presented on February 21, 2012 at the AAFS 64th Annual Scientific Meeting by Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services and Wendy R. Adams, Ph.D., DABFT, Forensic Toxicologist <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/pharmofsyntheticcann021712-120306102410-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Presented on February 21, 2012 at the AAFS 64th Annual Scientific Meeting by Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services and Wendy R. Adams, Ph.D., DABFT, Forensic Toxicologist
Pharmacodynamics and Pharmacokinetics of Synthetic Cannabinoids from NMS Labs
]]> 4438 8 https://cdn.slidesharecdn.com/ss_thumbnails/pharmofsyntheticcann021712-120306102410-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Designer Drugs Testing Solutions for Employers /nmslabs/designer-drugs-testing-solutions-for-employers huntsvilledesignerdrugsfinal-120206145010-phpapp01
Designer Drugs Testing Solutions for Employers Presented February 1, 2012 by Dr. Barry K. Logan, PhD, DABFT NMS Labs National Director of Forensic Services]]>
Designer Drugs Testing Solutions for Employers Presented February 1, 2012 by Dr. Barry K. Logan, PhD, DABFT NMS Labs National Director of Forensic Services]]> Mon, 06 Feb 2012 14:50:07 GMT /nmslabs/designer-drugs-testing-solutions-for-employers nmslabs@slideshare.net(nmslabs) Designer Drugs Testing Solutions for Employers nmslabs Designer Drugs Testing Solutions for Employers Presented February 1, 2012 by Dr. Barry K. Logan, PhD, DABFT NMS Labs National Director of Forensic Services <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/huntsvilledesignerdrugsfinal-120206145010-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Designer Drugs Testing Solutions for Employers Presented February 1, 2012 by Dr. Barry K. Logan, PhD, DABFT NMS Labs National Director of Forensic Services
Designer Drugs Testing Solutions for Employers from NMS Labs
]]> 1805 10 https://cdn.slidesharecdn.com/ss_thumbnails/huntsvilledesignerdrugsfinal-120206145010-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Oral Fluid as a Chemical Test for the DRE Program /slideshow/oral-fluid-as-a-chemical-test-for-the-dre-program/8718216 oralfluidstalkmontrealdre2011-110728153348-phpapp01
History, the Future, and Practical Considerations. Presented by Barry K Logan PhD, DABFT, National Director of Forensic Services, NMS Labs, Willow Grove, PA at the 2011 IACP-DRE Conference in Montreal, Canada. ]]>
History, the Future, and Practical Considerations. Presented by Barry K Logan PhD, DABFT, National Director of Forensic Services, NMS Labs, Willow Grove, PA at the 2011 IACP-DRE Conference in Montreal, Canada. ]]> Thu, 28 Jul 2011 15:33:42 GMT /slideshow/oral-fluid-as-a-chemical-test-for-the-dre-program/8718216 nmslabs@slideshare.net(nmslabs) Oral Fluid as a Chemical Test for the DRE Program nmslabs History, the Future, and Practical Considerations. Presented by Barry K Logan PhD, DABFT, National Director of Forensic Services, NMS Labs, Willow Grove, PA at the 2011 IACP-DRE Conference in Montreal, Canada. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/oralfluidstalkmontrealdre2011-110728153348-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> History, the Future, and Practical Considerations. Presented by Barry K Logan PhD, DABFT, National Director of Forensic Services, NMS Labs, Willow Grove, PA at the 2011 IACP-DRE Conference in Montreal, Canada.
Oral Fluid as a Chemical Test for the DRE Program from NMS Labs
]]> 56589 7 https://cdn.slidesharecdn.com/ss_thumbnails/oralfluidstalkmontrealdre2011-110728153348-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Developments in Toxicology Support for the DRE Community /slideshow/developments-in-toxicology-support-for-the-dre-community/8718155 dredragernmslabsinnovations-110728152719-phpapp01
NMS Labs and Draeger Safety Diagnostics announce a partnership formed to deliver the Total Oral Fluid Drug Testing Solution. Presented by Barry K. Logan PhD, DABFT, National Director of Forensic Services, NMS Labs - July 2011..]]>
NMS Labs and Draeger Safety Diagnostics announce a partnership formed to deliver the Total Oral Fluid Drug Testing Solution. Presented by Barry K. Logan PhD, DABFT, National Director of Forensic Services, NMS Labs - July 2011..]]> Thu, 28 Jul 2011 15:27:15 GMT /slideshow/developments-in-toxicology-support-for-the-dre-community/8718155 nmslabs@slideshare.net(nmslabs) Developments in Toxicology Support for the DRE Community nmslabs NMS Labs and Draeger Safety Diagnostics announce a partnership formed to deliver the Total Oral Fluid Drug Testing Solution. Presented by Barry K. Logan PhD, DABFT, National Director of Forensic Services, NMS Labs - July 2011.. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/dredragernmslabsinnovations-110728152719-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> NMS Labs and Draeger Safety Diagnostics announce a partnership formed to deliver the Total Oral Fluid Drug Testing Solution. Presented by Barry K. Logan PhD, DABFT, National Director of Forensic Services, NMS Labs - July 2011..
Developments in Toxicology Support for the DRE Community from NMS Labs
]]> 1405 6 https://cdn.slidesharecdn.com/ss_thumbnails/dredragernmslabsinnovations-110728152719-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 K2 and Beyond: A Synthetic Cannabinoid Primer /slideshow/k2-and-beyond-a-synthetic-cannabinoid-primer/7123951 nmscontributionstosyntheticcannabinoidworkshop-110302134911-phpapp02
Presented by NMS Labs at the AAFS Annual Conference, February 2011, by Dr. Barry Logan, Lindsay Reinhold, and Dr. Sherri Kacinko]]>
Presented by NMS Labs at the AAFS Annual Conference, February 2011, by Dr. Barry Logan, Lindsay Reinhold, and Dr. Sherri Kacinko]]> Wed, 02 Mar 2011 13:49:04 GMT /slideshow/k2-and-beyond-a-synthetic-cannabinoid-primer/7123951 nmslabs@slideshare.net(nmslabs) K2 and Beyond: A Synthetic Cannabinoid Primer nmslabs Presented by NMS Labs at the AAFS Annual Conference, February 2011, by Dr. Barry Logan, Lindsay Reinhold, and Dr. Sherri Kacinko <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/nmscontributionstosyntheticcannabinoidworkshop-110302134911-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Presented by NMS Labs at the AAFS Annual Conference, February 2011, by Dr. Barry Logan, Lindsay Reinhold, and Dr. Sherri Kacinko
K2 and Beyond: A Synthetic Cannabinoid Primer from NMS Labs
]]> 5028 23 https://cdn.slidesharecdn.com/ss_thumbnails/nmscontributionstosyntheticcannabinoidworkshop-110302134911-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical Analysis /slideshow/k2-and-synthetic-cannabinoids-pharmacology-effectschemical-analysis/6618294 k2andsyntheticcannabinoidspharmacologyeffectschemicalanalysis-110118150359-phpapp02
Presented September 16, 2010 by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services NMS Labs has responded to the recent explosive growth in popularity of synthetic cannabinoid agonists in so-called herbal blends by developing new tests for the active chemicals in botanical material, and most recently for the parent drugs and their metabolites in blood and urine. This presentation describes the history and origin of the chemicals of concern, the composition of the various commercial products containing them, their known pharmacology, and the documented effects on drivers, and human test subjects. We also review the adverse effects that have resulted in hospitalization, and even allegedly in deaths. This presentation describes the challenges around providing a chemical test for these new drugs, information on their stability in biological fluids, and the validation of quantitative methods for their determination.]]>
Presented September 16, 2010 by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services NMS Labs has responded to the recent explosive growth in popularity of synthetic cannabinoid agonists in so-called herbal blends by developing new tests for the active chemicals in botanical material, and most recently for the parent drugs and their metabolites in blood and urine. This presentation describes the history and origin of the chemicals of concern, the composition of the various commercial products containing them, their known pharmacology, and the documented effects on drivers, and human test subjects. We also review the adverse effects that have resulted in hospitalization, and even allegedly in deaths. This presentation describes the challenges around providing a chemical test for these new drugs, information on their stability in biological fluids, and the validation of quantitative methods for their determination.]]> Tue, 18 Jan 2011 15:03:56 GMT /slideshow/k2-and-synthetic-cannabinoids-pharmacology-effectschemical-analysis/6618294 nmslabs@slideshare.net(nmslabs) K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical Analysis nmslabs Presented September 16, 2010 by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services NMS Labs has responded to the recent explosive growth in popularity of synthetic cannabinoid agonists in so-called herbal blends by developing new tests for the active chemicals in botanical material, and most recently for the parent drugs and their metabolites in blood and urine. This presentation describes the history and origin of the chemicals of concern, the composition of the various commercial products containing them, their known pharmacology, and the documented effects on drivers, and human test subjects. We also review the adverse effects that have resulted in hospitalization, and even allegedly in deaths. This presentation describes the challenges around providing a chemical test for these new drugs, information on their stability in biological fluids, and the validation of quantitative methods for their determination. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/k2andsyntheticcannabinoidspharmacologyeffectschemicalanalysis-110118150359-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Presented September 16, 2010 by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services NMS Labs has responded to the recent explosive growth in popularity of synthetic cannabinoid agonists in so-called herbal blends by developing new tests for the active chemicals in botanical material, and most recently for the parent drugs and their metabolites in blood and urine. This presentation describes the history and origin of the chemicals of concern, the composition of the various commercial products containing them, their known pharmacology, and the documented effects on drivers, and human test subjects. We also review the adverse effects that have resulted in hospitalization, and even allegedly in deaths. This presentation describes the challenges around providing a chemical test for these new drugs, information on their stability in biological fluids, and the validation of quantitative methods for their determination.
K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical Analysis from NMS Labs
]]> 6186 5 https://cdn.slidesharecdn.com/ss_thumbnails/k2andsyntheticcannabinoidspharmacologyeffectschemicalanalysis-110118150359-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Salvia: Effects, Legal Status and Analysis /slideshow/salvia-effects-legal-status-and-analysis/6602024 salviaeffectslegalstatusandanalysiswebinar-110117110700-phpapp01
Presented March 18, 2010 by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services This presentation reviews the rising popularity and spread of Salvia divinorum, from its origins in religious ceremonies to its current status as a potent recreational hallucinogenic drug. The intense dissociative effects of the drug are described, the consequences of long term use, and its forensic significance considered. The presentation also assesses the efforts by various jurisdictions to schedule and outlaw the drug, and presents approaches to chemical and toxicological analysis of its active ingredients and metabolites, Salvinorins A and B.]]>
Presented March 18, 2010 by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services This presentation reviews the rising popularity and spread of Salvia divinorum, from its origins in religious ceremonies to its current status as a potent recreational hallucinogenic drug. The intense dissociative effects of the drug are described, the consequences of long term use, and its forensic significance considered. The presentation also assesses the efforts by various jurisdictions to schedule and outlaw the drug, and presents approaches to chemical and toxicological analysis of its active ingredients and metabolites, Salvinorins A and B.]]> Mon, 17 Jan 2011 11:06:54 GMT /slideshow/salvia-effects-legal-status-and-analysis/6602024 nmslabs@slideshare.net(nmslabs) Salvia: Effects, Legal Status and Analysis nmslabs Presented March 18, 2010 by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services This presentation reviews the rising popularity and spread of Salvia divinorum, from its origins in religious ceremonies to its current status as a potent recreational hallucinogenic drug. The intense dissociative effects of the drug are described, the consequences of long term use, and its forensic significance considered. The presentation also assesses the efforts by various jurisdictions to schedule and outlaw the drug, and presents approaches to chemical and toxicological analysis of its active ingredients and metabolites, Salvinorins A and B. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/salviaeffectslegalstatusandanalysiswebinar-110117110700-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Presented March 18, 2010 by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services This presentation reviews the rising popularity and spread of Salvia divinorum, from its origins in religious ceremonies to its current status as a potent recreational hallucinogenic drug. The intense dissociative effects of the drug are described, the consequences of long term use, and its forensic significance considered. The presentation also assesses the efforts by various jurisdictions to schedule and outlaw the drug, and presents approaches to chemical and toxicological analysis of its active ingredients and metabolites, Salvinorins A and B.
Salvia: Effects, Legal Status and Analysis from NMS Labs
]]> 1838 2 https://cdn.slidesharecdn.com/ss_thumbnails/salviaeffectslegalstatusandanalysiswebinar-110117110700-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 New Highs: Salvia and K 2 - Solutions for the DRE /slideshow/new-highs-salvia-and-k-2-solutions-for-the-dre/6601912 salviaandk2solutionsfordreprogram-110117105658-phpapp01
Presented July 2010 at the IACP DRE Conference to Drug Recognition Experts across the nation by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services]]>
Presented July 2010 at the IACP DRE Conference to Drug Recognition Experts across the nation by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services]]> Mon, 17 Jan 2011 10:56:47 GMT /slideshow/new-highs-salvia-and-k-2-solutions-for-the-dre/6601912 nmslabs@slideshare.net(nmslabs) New Highs: Salvia and K 2 - Solutions for the DRE nmslabs Presented July 2010 at the IACP DRE Conference to Drug Recognition Experts across the nation by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/salviaandk2solutionsfordreprogram-110117105658-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Presented July 2010 at the IACP DRE Conference to Drug Recognition Experts across the nation by Dr. Barry K. Logan, PhD, DABFT, NMS Labs National Director of Forensic Services
New Highs: Salvia and K 2 - Solutions for the DRE from NMS Labs
]]> 1212 9 https://cdn.slidesharecdn.com/ss_thumbnails/salviaandk2solutionsfordreprogram-110117105658-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Testing for BPA and other EDCs /slideshow/testing-for-ed-cs/6195165 testingforedcs-101216110232-phpapp01
Testing for Bisphenol A and other Endocrine Disruptor Chemicals Lee Blum, Ph.D.]]>
Testing for Bisphenol A and other Endocrine Disruptor Chemicals Lee Blum, Ph.D.]]> Thu, 16 Dec 2010 11:02:25 GMT /slideshow/testing-for-ed-cs/6195165 nmslabs@slideshare.net(nmslabs) Testing for BPA and other EDCs nmslabs Testing for Bisphenol A and other Endocrine Disruptor Chemicals Lee Blum, Ph.D. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/testingforedcs-101216110232-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Testing for Bisphenol A and other Endocrine Disruptor Chemicals Lee Blum, Ph.D.
Testing for BPA and other EDCs from NMS Labs
]]> 691 4 https://cdn.slidesharecdn.com/ss_thumbnails/testingforedcs-101216110232-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10 /slideshow/nms-labs-dinner-presentation-by-dr-andrea-gore-52710/6194933 dinnerpresentationfromdr-gore-nms5-27-10-101216104745-phpapp01
Bisphenol A and other suspected estrogenic endocrine disruptors Andrea C. Gore Ph.D., University of Texas at Austin]]>
Bisphenol A and other suspected estrogenic endocrine disruptors Andrea C. Gore Ph.D., University of Texas at Austin]]> Thu, 16 Dec 2010 10:47:41 GMT /slideshow/nms-labs-dinner-presentation-by-dr-andrea-gore-52710/6194933 nmslabs@slideshare.net(nmslabs) NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10 nmslabs Bisphenol A and other suspected estrogenic endocrine disruptors Andrea C. Gore Ph.D., University of Texas at Austin <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/dinnerpresentationfromdr-gore-nms5-27-10-101216104745-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Bisphenol A and other suspected estrogenic endocrine disruptors Andrea C. Gore Ph.D., University of Texas at Austin
NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10 from NMS Labs
]]> 866 4 https://cdn.slidesharecdn.com/ss_thumbnails/dinnerpresentationfromdr-gore-nms5-27-10-101216104745-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 NMS Labs introduction /slideshow/nms-labs-introduction/6194666 nmslabsintroductiong-101216103508-phpapp01
Bisphenol-A and Other Suspected Estrogenic Endocrine Disruptors Dinner Program Hosted by NMS Labs ]]>
Bisphenol-A and Other Suspected Estrogenic Endocrine Disruptors Dinner Program Hosted by NMS Labs ]]> Thu, 16 Dec 2010 10:35:05 GMT /slideshow/nms-labs-introduction/6194666 nmslabs@slideshare.net(nmslabs) NMS Labs introduction nmslabs Bisphenol-A and Other Suspected Estrogenic Endocrine Disruptors Dinner Program Hosted by NMS Labs <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/nmslabsintroductiong-101216103508-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Bisphenol-A and Other Suspected Estrogenic Endocrine Disruptors Dinner Program Hosted by NMS Labs
NMS Labs introduction from NMS Labs
]]> 960 6 https://cdn.slidesharecdn.com/ss_thumbnails/nmslabsintroductiong-101216103508-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 https://cdn.slidesharecdn.com/profile-photo-nmslabs-48x48.jpg?cb=1523010235 Innovative, results-driven Director of Marketing passionate about being a change-agent and empowering patients and physicians within the healthcare industry. Strong leader with proven track record of formulating successful strategic directions and establishing ground-up B-to-B and B-to-C marketing operations. Exceptional at leading and managing all aspects of new product development, strategic partnerships and flawless executions. Outstanding at forming teams & leading large, complex strategic initiatives. Skilled at building company value through innovative insights, accountability, personal integrity and collaborative tenacity. www.nmslabs.com https://cdn.slidesharecdn.com/ss_thumbnails/november2012nmslabscathinoneswebinar-130425141329-phpapp02-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/increasing-diversity-of-chemicals-in-synthetic-stimulant-and-cathinone-cases/19977103 Increasing Diversity o... https://cdn.slidesharecdn.com/ss_thumbnails/agilentoctobertofseminarupdated-121010142551-phpapp02-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/the-challenges-of-analytical-method-validation-for-hallucinogens-and-designer-stimulants-in-biological-samples-using-lctof/14673342 The Challenges of Anal... https://cdn.slidesharecdn.com/ss_thumbnails/designerdrugspringupdatebklwebinarmay2012-120525134751-phpapp02-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/trends-report-on-changes-in-the-designer-drug-market-spring-2012/13078610 Trends Report on Chang...